Probiodrug
Probiodrug celebrates one-year listing anniversary
Probiodrug (ticker symbol: PBD) opens trading at the Amsterdam exchange to mark one year from the first date of listing on Euronext and as a symbol of the company’s mission to find a treatment for Alzheimer´s disease (AD). The gong is sounded by Inge Lues, CDO Probiodrug, accompanied by Dr Konrad Glund, CEO and co‑founder of the company.
Probiodrug AG is a biopharmaceutical company focused on the development and commercialisation of new therapeutic products for the treatment of Alzheimer’s disease. Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund and successfully developed a novel therapeutic concept for diabetes. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients.
For more information: www.probiodrug.de